迪瑞医疗跌2.04%，成交额1507.91万元，主力资金净流入40.73万元

Core Viewpoint - The stock price of Di Rui Medical has experienced a significant decline this year, with a drop of 16.23% year-to-date and a 2.95% decrease over the past 20 days, indicating potential challenges in the company's performance and market perception [2]. Company Overview - Di Rui Medical Technology Co., Ltd. is located in Changchun, Jilin Province, and was established on December 26, 1994. The company was listed on September 10, 2014. Its main business involves the research, production, and sales of medical testing instruments and related test paper reagents [2]. - The revenue composition of Di Rui Medical is as follows: reagents account for 57.13%, instruments for 42.24%, and other sources for 0.63% [2]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector focusing on in vitro diagnostics. It is associated with several concept sectors, including small-cap stocks, hepatitis treatment, monkeypox concepts, medical devices, and Sino-Russian trade [2]. Financial Performance - For the period from January to September 2025, Di Rui Medical reported a revenue of 469 million yuan, representing a year-on-year decrease of 60.12%. The net profit attributable to the parent company was -87.25 million yuan, reflecting a significant decline of 145.31% compared to the previous year [2]. - As of September 30, 2025, the company had a total of 16,800 shareholders, a decrease of 6.48% from the previous period. The average number of circulating shares per shareholder increased by 6.92% to 16,159 shares [2]. Shareholder and Dividend Information - Di Rui Medical has distributed a total of 923 million yuan in dividends since its A-share listing, with 340 million yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders included a new entrant, Dachen Jingheng Mixed A (090019), holding 1.27 million shares, ranking as the ninth largest circulating shareholder [3].